<DOC>
	<DOCNO>NCT02513160</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy beclomethasone dipropionate administer via BAI dose strength 40 80 mcg per oral inhalation ( 320 640 mcg/day , respectively ) compare placebo treatment patient persistent asthma assess standardized baseline-adjusted trough morning ( pre-dose pre-rescue bronchodilator ) Forced expiratory volume 1 second ( FEV1 ) area effect curve time 0 6 week ( AUEC [ 0-6wk ] ) .</brief_summary>
	<brief_title>Study Assess Efficacy Safety Beclomethasone Dipropionate Adolescent Adult Patients 12 Years Age Older With Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>The patient diagnosis asthma define NIH . The asthma diagnosis present minimum 3 month stable ( defined exacerbation change medication ) least 30 day . The patient maintain stable dos : noncorticosteroid therapy inhale corticosteroid therapy Written inform consent/assent obtain . For adult patient ( 18 year age old , applicable per local regulation ) , write informed consent form ( ICF ) must sign dated patient conduct studyrelated procedure . For minor patient ( age 12 17 year , applicable per local regulation ) , write ICF must sign dated parent/legal guardian write informed assent form must sign dated patient conduct studyrelated procedure . The patient male female 12 year age old visit inform consent/assent sign ( screen prescreening visit , applicable ) . ( Note : Age requirement specify allow local regulation . ) The patient able perform acceptable repeatable spirometry The patient able use electronic diary training . The patient able use device properly If female , patient currently pregnant , breast feeding , attempt become pregnant ( 30 day screen visit ( SV ) throughout duration study 30 day patient 's last study visit ) , childbearing potential sexually active , negative urine pregnancy test , willing commit use consistent acceptable method birth control If male , patient willing commit acceptable method birth control duration study , surgically sterile exclusively samesex partner ( ) . The patient concomitant condition treatment could interfere study conduct , influence interpretation study observations/results , put patient increase risk study judge investigator . The patient/parent/legal guardian capable understanding requirement , risk , benefit study participation , , judge investigator , capable give informed consent/assent compliant study requirement ( eg , dose schedule , visit schedule , procedure , record keep ) . The patient , judge investigator , able discontinue asthma medication SV . criterion apply , please contact investigator information Exclusion Criteria Lifethreatening asthma , define history asthma episode ( ) require intubation and/or associate hypercapnea , respiratory arrest hypoxic seizure , asthmarelated syncopal episode ( ) , hospitalization within past year . The patient receive systemic corticosteroid within 30 day SV ( asthma exacerbation indication ) . The patient participate investigational drug study randomize patient within 30 day ( start final visit study ) precede SV ( prescreening visit , applicable ) , plan participate another investigational drug study time study . The patient previously participate beclomethasone dipropionate breathactuated inhaler ( device ) ( BAI ) study randomize patient . The patient know hypersensitivity corticosteroid excipients study drug rescue medication formulation . The patient treat know strong cytochrome inhibitor study . The patient treat prohibited medication prescribe ( per protocol ) withdrawal period SV . The patient currently smoke smoke history 10 pack year ( pack year define smoke 1 pack cigarettes/day 1 year ) . The patient may use tobacco product within past year ( eg , cigarette , cigar , chew tobacco , pipe tobacco ) . The patient suspect bacterial viral infection upper low respiratory tract , sinus , middle ear resolve least 2 week SV . The patient history alcohol drug abuse within 2 year precede SV . The patient asthma exacerbation require oral corticosteroid within 1 month SV , hospitalization asthma within 3 month SV . The patient initiate immunotherapy ( administer route ) less 90 day SV dose escalation immunotherapy le 30 day SV . The patient unable tolerate unwilling comply require washout period withhold applicable medication . The patient untreated oral candidiasis SV . Patients clinical visual evidence oral candidiasis agree receive treatment comply appropriate medical monitoring may enter study . The patient either employee immediate relative employee clinical investigational center . A member patient 's household participate study time . ( However , enrol patient completes discontinues participation study , another patient household may screen ) . The patient disease/condition , medical judgment investigator , would put safety patient risk participation could affect efficacy safety analysis disease/condition worsen study . criterion apply , please contact investigator information</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>